Zhu Liangxue, Kong Yuanyuan, Xing Yajun, Wang Mingyun
Department of Oncology, Nanjing Gaochun People's Hospital, Nanjing, 211300, People's Republic of China.
Int J Gen Med. 2025 Jun 24;18:3363-3372. doi: 10.2147/IJGM.S529776. eCollection 2025.
In this retrospective study, we aimed to investigate the prognostic and early efficacy prediction value of baseline CALLY index in advanced pancreatic cancer.
We analyzed the clinical and follow-up data of 252 metastatic pancreatic cancer patients diagnosed at Nanjing Gaochun People's Hospital from January 2019 to June 2024. The optimal cut-off for the CALLY index was determined by maximizing Youden's index (J = sensitivity + specificity - 1) through receiver operating characteristic (ROC) curve analysis. Early treatment efficacy was evaluated according to RECIST 1.1 criteria based on radiological assessments at 6~9 weeks after initiating first-line therapy. The effect of the CALLY index on survival and early efficacy in first-line treatment was analyzed using the Kaplan-Meier method and the Cox proportional hazards model. The CALLY index was calculated as: (Albumin × Lymphocyte)/(CRP × 104).
The cut-off value of the CALLY index for predicting survival was determined at 0.27. The area under the curve (AUC) was 0.725. With a cut-off value of 0.27, patients were divided into two groups: those with CALLY ≥0.27 and those with CALLY <0.27. The median overall survival was 12 and 5 months respectively (P < 0.01). CALLY Index ≥ 0.27 was associated with better survival outcomes. Cox regression analysis revealed that a low CALLY index (<0.27) was independent predictors of poor prognosis. CALLY index of 0.27 for predicting early efficacy in advanced pancreatic cancer patients with an area under the curve (AUC) of 0.73, and there was a statistically significant difference in early efficacy of first-line therapy between the high and low CALLY groups (P = 0.022).
Our findings suggest that the baseline CALLY index is a promising predictive biomarker for early efficacy and prognosis of patients with Pancreatic cancer, though its reliability requires validation in multicenter prospective studies.
在这项回顾性研究中，我们旨在探讨基线CALLY指数在晚期胰腺癌中的预后及早期疗效预测价值。
我们分析了2019年1月至2024年6月在南京高淳人民医院确诊的252例转移性胰腺癌患者的临床及随访数据。通过受试者工作特征（ROC）曲线分析最大化约登指数（J = 灵敏度 + 特异度 - 1）来确定CALLY指数的最佳截断值。根据RECIST 1.1标准，在一线治疗开始后6至9周基于影像学评估来评估早期治疗疗效。使用Kaplan-Meier法和Cox比例风险模型分析CALLY指数对一线治疗生存及早期疗效的影响。CALLY指数计算方法为：（白蛋白×淋巴细胞）/（C反应蛋白×104）。
预测生存的CALLY指数截断值确定为0.27。曲线下面积（AUC）为0.725。以0.27为截断值，患者被分为两组：CALLY≥0.27组和CALLY<0.27组。中位总生存期分别为12个月和5个月（P<0.01）。CALLY指数≥0.27与更好的生存结果相关。Cox回归分析显示，低CALLY指数（<0.27）是预后不良的独立预测因素。预测晚期胰腺癌患者早期疗效的CALLY指数为0.27，曲线下面积（AUC）为0.73，CALLY高低组一线治疗早期疗效存在统计学显著差异（P = 0.022）。
我们的研究结果表明，基线CALLY指数是胰腺癌患者早期疗效和预后的一个有前景的预测生物标志物，尽管其可靠性需要在多中心前瞻性研究中进行验证。
